Simplifying Global Compliance
FDA Advisory Panel Backs Approval of Pfizer, Affymax Drugs
Washington Drug Letter
An FDA advisory committee unanimously backed Pfizer’s kidney cancer drug Inlyta as a second-line treatment for patients with advanced renal cell carcinoma (RCC).
To View This Article:
Buy This Article Now
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing